Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10576592 | 0.91 | MEN1 (0.38) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL11813613 | 0.85 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL2989785 | 0.85 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL7533743 | 0.84 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL5857211 | 0.83 | MEN1 (0.34) | MEN1KMT2AKDM4CGRM5 | |
| SCHEMBL21641751 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4CGRM5 | |
| SCHEMBL1227411 | 0.82 | MEN1 (0.34) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL1921106 | 0.82 | MEN1 (0.34) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL21437122 | 0.82 | MEN1 (0.37) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL2984108 | 0.82 | MEN1 (0.37) | MEN1KMT2AKDM4CGRM5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3940425-A | Process for the production of polyunsaturated compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-24 | — | — | US | claimed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3774789-B1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4038066-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114787159-A | BRM targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20120136057-A1 | HYDROXY FATTY ACID COMPOUNDS AND USES THEREOF FOR DISEASE TREATMENT AND DIAGNOSIS | PHENOMENOME DISCOVERIES INC. (CA) | 2012-05-31 | — | — | US | disclosed |
| US-7241784-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20040087636-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-05-06 | — | — | US | disclosed |
| US-6664281-B1 | Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-1108713-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
| EP-0479640-A2 | Novel phosphonate derivatives of certain nucleosides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0477454-A1 | Novel phosphonate derivatives of certain nucleosides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| US-4867915-A | LIPOXYGENASE INHIBITORS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4670465-A | ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-3940425-A | Process for the production of polyunsaturated compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087636-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | PPARA, PPARG, PPARD | MEN1 4816/4885KMT2A 1688/4885KDM4C 3971/4885 |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | MEN1 2768/4885KMT2A 874/4885KDM4C 2685/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | MEN1 3886/4885KMT2A 1067/4885KDM4C 2478/4885 |
| US-20120136057-A1 | HYDROXY FATTY ACID COMPOUNDS AND USES THEREOF FOR DISEASE TREATMENT AND DIAGNOSIS | HCAR2, ALOX5, ALOX12 | MEN1 2547/4885KMT2A 3613/4885KDM4C 3756/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | MEN1 4186/4885KMT2A 928/4885KDM4C 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.